ERBB2 and neoplasm: Targeted therapy inhibits tumor driver mutations or overexpressed antigens, such as human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF) or transforming growth factor-β (TGF-β) receptor.